Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 75

Results For "RMAT"

1996 News Found

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025
Policy | June 09, 2025

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme


Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life
News | June 07, 2025

Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life

Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life


Sun Pharma discontinue development of SCD-044 drug after trial disappointment
Clinical Trials | June 05, 2025

Sun Pharma discontinue development of SCD-044 drug after trial disappointment

Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis


Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration
News | June 05, 2025

Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types


Sanofi exercises license extension option to Nurix’s STAT6 program
Biopharma | June 04, 2025

Sanofi exercises license extension option to Nurix’s STAT6 program

his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days


iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
Clinical Trials | June 04, 2025

iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients

The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure


Sigachi Industries FY25 revenue surges 25%, EBITDA 46%
News | June 02, 2025

Sigachi Industries FY25 revenue surges 25%, EBITDA 46%

Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients


Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
News | June 02, 2025

Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio


Merck withdraws Biologics License Application for Patritumab Deruxtecan
Drug Approval | May 30, 2025

Merck withdraws Biologics License Application for Patritumab Deruxtecan

The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance